Financial Results Briefing Materials for the Fiscal Year Ending March 2026

Overview of Results

For the fiscal year ended March 2026, consolidated net sales were JPY 8,665 million, operating loss was JPY 2,073 million, and net loss attributable to owners of the parent was JPY 3,329 million. Revenue declined significantly due to delays in large-scale international joint trials in the U.S. and Europe, and goodwill impairment was recognized in Europe. By region, Japan posted higher sales while the loss narrowed; the U.S. and Europe faced declines in revenue and widened losses.

Outlook for the Fiscal Year Ending March 2027 and Capital Policy

The full-year plan contemplates net sales of JPY 10,680 million, operating profit of JPY 256 million, and net income attributable to owners of the parent of JPY 180 million, aiming to achieve a return to profitability on the assumption of recovery in the U.S. and Europe and growth in Asia. Dividends are planned to continue at JPY 8.00 per share. The capital policy emphasizes strengthening the financial base while balancing shareholder returns, maintaining and improving the equity ratio, and enabling flexible fund-raising.